150 results on '"Damato, Valentina"'
Search Results
2. Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome
3. Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience
4. Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
5. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
6. Benefit and danger from immunotherapy in myasthenia gravis
7. Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation.
8. An insight into the mechanical properties of selected commercial oil and alkyd paint films containing cobalt blue
9. Disease specific enrichment of circulating let-7 family microRNA in MuSK + myasthenia gravis
10. Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab
11. Serological and experimental studies in different forms of myasthenia gravis
12. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients
13. Myasthenia gravis with antibodies to MuSK: an update
14. Conventional and emerging treatments and controversies in myasthenia gravis.
15. 275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9–11 February 2024, Hoofddorp, the Netherlands
16. Pattern of ocular involvement in myasthenia gravis with MuSK antibodies
17. Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment
18. Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update.
19. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
20. Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations
21. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody- associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and metaanalysis.
22. B cell related predictive biomarkers of treatment response in myasthenia gravis
23. Demographic changes in myasthenia gravis over the last 20 years: A single center experience
24. Teaching Video NeuroImage: The "Chameleon Eyes Sign" in Myasthenia Gravis.
25. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis.
26. Long-term-video monitoring EEG and 18F-FDG-PET are useful tools to detect residual disease activity in anti-LGI1-Abs encephalitis: A case report.
27. Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis.
28. Safety and tolerability of SARS‐Cov‐2 vaccination in patients with myasthenia gravis: A multicenter experience.
29. Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies
30. Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders.
31. Tissue-Infiltrating Lymphocytes Analysis Reveals Large Modifications of the Duodenal “Immunological Niche” in Coeliac Disease After Gluten-Free Diet
32. Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia.
33. Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors.
34. Heterogeneity in myasthenia gravis: considerations for disease management.
35. Human Leukocyte Antigen Class II associations in late‐onset Myasthenia Gravis.
36. Myasthenia gravis associated with anti‐MuSK antibodies developed after SARS‐CoV‐2 infection.
37. Il ruolo dei siccativi nel comportamento delle pitture ad olio commerciali del XX secolo
38. Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment
39. Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis
40. Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma
41. The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders.
42. Type 1 immune response in progressive multiple sclerosis
43. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders.
44. Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review
45. Response to: "MuSK‐positive myasthenia may be triggered not only by SARS‐CoV‐2".
46. Poly-autoimmunity in patients with myasthenia gravis: A single-center experience.
47. Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.
48. Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies
49. Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders.
50. Uveitis: A snapshot in the MOG antibody spectrum.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.